RVX:TSX

Resverlogix Corp.

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. The company's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Resverlogix can be followed on its blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX

Expert Comments:

"Resverlogix Corp. is active in targeting cardiovascular disease. It has a proprietary drug development platform that's based on targeting bromodomain and extra terminal (BET) domain proteins. BET proteins have potential in many diseases, including cardiovascular disease, neurodegenerative disease and diabetes. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. . .using epigenetics (to target cardiovascular disease) is getting more emphasis from scientists and cardio specialists. The approach being developed by Resverlogix is a small molecule that can uncover the involved environmental and individual aspects of lifestyle that directly interact with the genome to influence epigenetic change in the DNA of a person. The company is targeting patients who have diabetes mellitus or chronic kidney failure who are at high risk for cardiovascular disease. . .the company may have the answer to developing a new generation of cardio drugs. . ." read more >

Jason Napodano, Zacks Equity Research (4/20/15)
"Resverlogix Corp. is addressing the major problem of the unmet need in cardiovascular management. . .while the majority of current therapies aim to manage glucose levels in diabetic patients, the company is taking a unique approach by looking at it from the point of view of reducing Major Adverse Cardiac Events (MACE)—the primary killer in both men and women. . .furthermore, chronic kidney disease is an extension of diabetes and also results in high cardiovascular disease death rates, which Resverlogix is also looking to solve."

Bjarke Krysel Christensen, Seeking Alpha (4/8/15)
"The pooled results from two recent Phase 2 clinical trials with Resverlogix Corp.'s RVX-208 indicated that treatment resulted in a drastic and statistically significant reduction of major adverse cardiac events in a patient population with established atherosclerosis. . .a subgroup analysis of patients who were given RVX-208 in combination with AstraZeneca's Crestor showed a statistically significant degree of plaque regression. . .keeping in mind that these promising results and the results from the diabetes mellitus subpopulation of patients were the result of a post hoc analysis, there has to be a very compelling explanation rooted in RVX-208's mode of action for anyone to make an investment in Resverlogix."

Dan Trang, Stonegate Capital Partners (4/1/15)
"Resverlogix Corp. expects to start its trial that should validate RVX-208's safety profile. If the results are positive, it could be promising for its commercialization efforts and could also expand to other indications beyond diabetes. . .the company is uniquely positioned to leverage its novel molecule, RVX-208, in cardiovascular disease, particularly atherosclerosis, and hopefully later in Alzheimer’s disease and diabetes."

Marcel Wijma, Van Leeuwenhoeck Research (3/16/15)
"We believe Resverlogix Corp. is substantially undervalued at the current share price. . .this represents an enormous upside. . .with a successful Phase 3 trial and considering the market potential for RVX-208, we feel that a very significant upside potential for RVX-208 and the company is attainable."

Experts Commenting on This Company

Jason Napodano, Managing Director and Senior Biotech Analyst – Zacks Investment Research
Dan Trang – Stonegate Securities
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
 
Phase 3 Status from European Regulatory Authority for BETonMACE Clinical Trial
 
Combination Licensing and Equity Arrangement with China-Based Shenzhen Hepalink Pharmaceutical Co., Ltd.
 
Two Patents for RVX-208 in China
catalyst Calendar
Resverlogix Corp. Content